Kristy A Brown1, Neil M Iyengar2,3, Xi Kathy Zhou4, Ayca Gucalp2,3, Kotha Subbaramaiah3, Hanhan Wang4, Dilip D Giri5, Monica Morrow6, Domenick J Falcone7, Nils K Wendel3, Lisle A Winston3, Michael Pollak8, Anneloor Dierickx3, Clifford A Hudis2,3, Andrew J Dannenberg3. 1. Metabolism and Cancer Laboratory, Centre for Cancer Research, Hudson Institute of Medical Research, and Monash University, Clayton, Victoria 3168, Australia. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065. 3. Department of Medicine, Weill Cornell Medical College, New York, New York 10065. 4. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York 10065. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065. 6. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065. 7. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10065. 8. Departments of Medicine and Oncology, McGill University, Montreal, Quebec, Canada H3T 1E2.
Abstract
Context: Most estrogen-dependent breast cancers occur after menopause, despite low levels of circulating estrogens. Breast expression of the estrogen-biosynthetic enzyme, aromatase, is proposed to drive breast cancer development after menopause. However, the effects of menopause on breast aromatase expression are unknown. Objective: To determine the effect of menopause on breast aromatase expression in relation to body mass index (BMI), white adipose tissue inflammation (WATi), and systemic markers of metabolic dysfunction. Design, Setting, and Participants: Cross-sectional study of 102 premenopausal (age 27 to 56) and 59 postmenopausal (age 45 to 74) women who underwent mastectomy for breast cancer treatment/prevention. Outcome: Breast tissue was assessed for the presence of crown-like structures and the expression and activity of aromatase. Systemic markers examined include interleukin (IL)-6, insulin, glucose, leptin, adiponectin, high-sensitivity C-reactive protein (hsCRP), cholesterol, and triglycerides. Multivariable analysis was performed for aromatase messenger RNA (mRNA) in relation to BMI, WATi, and blood markers. Results: Postmenopausal women had higher BMI and more breast WATi than premenopausal women. Fasting levels of IL-6, glucose, leptin, hsCRP, and homeostatic model assessment 2 insulin resistance score were higher in the postmenopausal group. BMI was positively correlated with aromatase mRNA in both pre- and postmenopausal women. Aromatase levels were higher in breast tissue of postmenopausal women, with levels being higher in inflamed vs noninflamed, independent of BMI. Adipocyte diameter and levels of leptin, hsCRP, adiponectin, and high-density lipoprotein cholesterol were more strongly correlated with aromatase in postmenopausal than premenopausal women. Conclusions: Elevated aromatase in the setting of adipose dysfunction provides a possible mechanism for the higher incidence of hormone-dependent breast cancer in obese women after menopause.
Context: Most estrogen-dependent breast cancers occur after menopause, despite low levels of circulating estrogens. Breast expression of the estrogen-biosynthetic enzyme, aromatase, is proposed to drive breast cancer development after menopause. However, the effects of menopause on breast aromatase expression are unknown. Objective: To determine the effect of menopause on breast aromatase expression in relation to body mass index (BMI), white adipose tissue inflammation (WATi), and systemic markers of metabolic dysfunction. Design, Setting, and Participants: Cross-sectional study of 102 premenopausal (age 27 to 56) and 59 postmenopausal (age 45 to 74) women who underwent mastectomy for breast cancer treatment/prevention. Outcome: Breast tissue was assessed for the presence of crown-like structures and the expression and activity of aromatase. Systemic markers examined include interleukin (IL)-6, insulin, glucose, leptin, adiponectin, high-sensitivity C-reactive protein (hsCRP), cholesterol, and triglycerides. Multivariable analysis was performed for aromatase messenger RNA (mRNA) in relation to BMI, WATi, and blood markers. Results: Postmenopausal women had higher BMI and more breast WATi than premenopausal women. Fasting levels of IL-6, glucose, leptin, hsCRP, and homeostatic model assessment 2 insulin resistance score were higher in the postmenopausal group. BMI was positively correlated with aromatase mRNA in both pre- and postmenopausal women. Aromatase levels were higher in breast tissue of postmenopausal women, with levels being higher in inflamed vs noninflamed, independent of BMI. Adipocyte diameter and levels of leptin, hsCRP, adiponectin, and high-density lipoprotein cholesterol were more strongly correlated with aromatase in postmenopausal than premenopausal women. Conclusions: Elevated aromatase in the setting of adipose dysfunction provides a possible mechanism for the higher incidence of hormone-dependent breast cancer in obesewomen after menopause.
Authors: Saverio Cinti; Grant Mitchell; Giorgio Barbatelli; Incoronata Murano; Enzo Ceresi; Emanuela Faloia; Shupei Wang; Melanie Fortier; Andrew S Greenberg; Martin S Obin Journal: J Lipid Res Date: 2005-09-08 Impact factor: 5.922
Authors: Neil M Iyengar; Xi Kathy Zhou; Ayca Gucalp; Patrick G Morris; Louise R Howe; Dilip D Giri; Monica Morrow; Hanhan Wang; Michael Pollak; Lee W Jones; Clifford A Hudis; Andrew J Dannenberg Journal: Clin Cancer Res Date: 2015-12-28 Impact factor: 12.531
Authors: Robert M Blew; Luis B Sardinha; Laura A Milliken; Pedro J Teixeira; Scott B Going; Dawna L Ferreira; Margaret M Harris; Linda B Houtkooper; Timothy G Lohman Journal: Obes Res Date: 2002-08
Authors: J R Pasqualini; G Chetrite; C Blacker; M C Feinstein; L Delalonde; M Talbi; C Maloche Journal: J Clin Endocrinol Metab Date: 1996-04 Impact factor: 5.958
Authors: Neil M Iyengar; I-Chun Chen; Xi K Zhou; Dilip D Giri; Domenick J Falcone; Lisle A Winston; Hanhan Wang; Samantha Williams; Yen-Shen Lu; Tsu-Hsin Hsueh; Ann-Lii Cheng; Clifford A Hudis; Ching-Hung Lin; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2017-12-08
Authors: Ayca Gucalp; Xi K Zhou; Elise D Cook; Judy E Garber; Katherine D Crew; Julie R Nangia; Priya Bhardwaj; Dilip D Giri; Olivier Elemento; Akanksha Verma; Hanhan Wang; J Jack Lee; Lana A Vornik; Carrie Mays; Diane Weber; Valerie Sepeda; Holly O'Kane; Margaret Krasne; Samantha Williams; Patrick G Morris; Brandy M Heckman-Stoddard; Barbara K Dunn; Clifford A Hudis; Powel H Brown; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2018-02-16
Authors: Asra N Shaik; Katrin Kiavash; Karri Stark; Julie L Boerner; Julie J Ruterbusch; Hany Deirawan; Sudeshna Bandyopadhyay; Rouba Ali-Fehmi; Gregory Dyson; Michele L Cote Journal: Breast Cancer Res Treat Date: 2020-10-28 Impact factor: 4.872